Hechler Béatrice, Cattaneo Marco, Gachet Christian
INSERM, Etablissement Français du Sang-Alsace, 10 Rue Spielmann, BP 36-67065 Strasbourg Cedex, France.
Semin Thromb Hemost. 2005 Apr;31(2):150-61. doi: 10.1055/s-2005-869520.
After vessel wall injury, platelets adhere to the exposed subendothelium, are activated, and release mediators such as thromboxane A (2) (TXA (2)) and nucleotides stored at very high concentration in the so-called dense granules. Among other soluble agents, released nucleotides act in a positive feedback mechanism to cause further platelet activation and amplify platelet responses induced by agents such as thrombin or collagen. Adenine nucleotides act on platelets through three distinct P2 receptors: two are G protein-coupled adenosine diphosphate (ADP) receptors, namely the P2Y (1) and P2Y (12) receptor subtypes; the P2X (1) receptor ligand-gated cation channel is activated by adenosine triphosphate (ATP). The P2Y (1) receptor initiates platelet aggregation but is not sufficient for a full platelet aggregation in response to ADP, whereas the P2Y (12) receptor is responsible for completion of the aggregation to ADP. This receptor, the molecular target of the antithrombotic drug clopidogrel, is responsible for most of the potentiating effects of ADP when platelets are stimulated by agents such as thrombin, collagen, or immune complexes. The P2X (1) receptor is involved in platelet shape change and in activation by collagen under shear conditions. Each of these receptors is coupled to specific signal transduction pathways in response to ADP or ATP and is differentially involved in all of the sequential events involved in platelet function and hemostasis. As such, they represent potential targets for antithrombotic drugs.
血管壁损伤后,血小板黏附于暴露的内皮下层,被激活并释放介质,如血栓素A2(TXA2)和储存在所谓致密颗粒中高浓度的核苷酸。在其他可溶性因子中,释放的核苷酸通过正反馈机制进一步引起血小板激活,并放大由凝血酶或胶原蛋白等因子诱导的血小板反应。腺嘌呤核苷酸通过三种不同的P2受体作用于血小板:两种是G蛋白偶联的二磷酸腺苷(ADP)受体,即P2Y(1)和P2Y(12)受体亚型;P2X(1)受体配体门控阳离子通道由三磷酸腺苷(ATP)激活。P2Y(1)受体启动血小板聚集,但不足以对ADP产生完全的血小板聚集反应,而P2Y(12)受体负责完成对ADP的聚集反应。该受体是抗血栓药物氯吡格雷的分子靶点,当血小板受到凝血酶、胶原蛋白或免疫复合物等因子刺激时,它负责ADP的大部分增强作用。P2X(1)受体参与血小板形状改变以及在剪切条件下由胶原蛋白介导的激活。这些受体中的每一种都与响应ADP或ATP的特定信号转导途径偶联,并在血小板功能和止血所涉及的所有连续事件中发挥不同作用。因此,它们是抗血栓药物的潜在靶点。